As the pace of Fragile X research accelerates, FRAXA funded research teams are leading the way.
Our research spans the spectrum of basic science, pre-clinical, and clinical research — all coordinated to make the most of each dollar. We are developing several treatment strategies in parallel, since success is never certain when developing a drug. We continue to fund research to define the precise defect in the Fragile X brain, because these studies may yield additional important treatment targets.
In the words of FRAXA Scientific Advisor, Dr. Justin Fallon, “Fragile X is poised to become a triumph for translational research and the design of rational therapeutics for brain disease.”